Tau is an attractive target because patients with frontotemporal dementia and Parkinsonism-linked to chromosome-17 (FTDP-17) carry a mutation in the tau gene and display NFT and neuronal loss in the absence of Aβ deposition17, 18, 19. The gene discussed is MAPT; the disease is frontotemporal dementia.